[go: up one dir, main page]

ES2559007T3 - Alfa1 antitripsina humana recombinante - Google Patents

Alfa1 antitripsina humana recombinante Download PDF

Info

Publication number
ES2559007T3
ES2559007T3 ES10716318.0T ES10716318T ES2559007T3 ES 2559007 T3 ES2559007 T3 ES 2559007T3 ES 10716318 T ES10716318 T ES 10716318T ES 2559007 T3 ES2559007 T3 ES 2559007T3
Authority
ES
Spain
Prior art keywords
recombinant human
alpha1
human antitrypsin
glucans
antitrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10716318.0T
Other languages
English (en)
Inventor
Elisabeth C. M. Brinkman
Cornelis Erik Hack
Ingrid Van Den Nieuwenhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of ES2559007T3 publication Critical patent/ES2559007T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

α1-antitripsina humana recombinante (AAThr) que comprende glucanos unidos en N, caracterizado por que: (a) al menos el 10% de dichos glucanos unidos en N son glucanos tetra-antenarios; y (b) el grado de protección con ácido siálico en dichos glucanos unidos en N (Z/A) es de al menos el 50%, en la que al menos el 50% de la sialilación en dichos glucanos unidos en N es α-2,3-sialilación.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES10716318.0T 2009-04-23 2010-04-20 Alfa1 antitripsina humana recombinante Active ES2559007T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21449209P 2009-04-23 2009-04-23
US214492P 2009-04-23
EP09158640 2009-04-23
EP09158640 2009-04-23
PCT/EP2010/055177 WO2010127939A1 (en) 2009-04-23 2010-04-20 Recombinant human alpha1-antitrypsin

Publications (1)

Publication Number Publication Date
ES2559007T3 true ES2559007T3 (es) 2016-02-10

Family

ID=40929544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10716318.0T Active ES2559007T3 (es) 2009-04-23 2010-04-20 Alfa1 antitripsina humana recombinante

Country Status (14)

Country Link
US (1) US8357661B2 (es)
EP (1) EP2421895B1 (es)
JP (1) JP5711215B2 (es)
KR (1) KR101640962B1 (es)
CN (1) CN102439037B (es)
AU (1) AU2010244592B2 (es)
CA (1) CA2756591C (es)
DK (1) DK2421895T3 (es)
EA (1) EA025021B1 (es)
ES (1) ES2559007T3 (es)
IL (1) IL215537A (es)
PL (1) PL2421895T3 (es)
WO (1) WO2010127939A1 (es)
ZA (1) ZA201107416B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559007T3 (es) 2009-04-23 2016-02-10 Crucell Holland B.V. Alfa1 antitripsina humana recombinante
KR20140132706A (ko) * 2011-12-19 2014-11-18 엘에프비 유에스에이, 인크. 염증성 장애의 치료를 위한 재조합 인간 알파-1-안티트립신
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
CN102994514B (zh) * 2012-11-07 2015-06-10 武汉禾元生物科技股份有限公司 一种从水稻种子生产和分离纯化重组人抗胰蛋白酶(OsrAAT)的方法
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
US12031144B2 (en) 2017-03-29 2024-07-09 Cornell University Oxidation-resistant AAT gene therapy
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP3717640A1 (en) 2017-11-28 2020-10-07 Danmarks Tekniske Universitet Glycosylation of proteins
AU2020211080A1 (en) * 2019-01-24 2021-08-05 Excellgene Sa Methods of producing and using recombinant alpha 1-antitrypsin (AAT) and compositions thereof
WO2024075112A1 (en) * 2022-10-06 2024-04-11 Kamada Ltd. Highly fucosylated recombinant human alpha 1 antitrypsin (aat) protein having immunomodulatory activity and compositions comprising the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
DK1533380T3 (da) 1999-04-15 2010-02-01 Crucell Holland Bv Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CN100547069C (zh) * 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
CN101090973B (zh) * 2004-12-30 2012-03-28 克鲁塞尔荷兰公司 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质
WO2007102432A1 (ja) * 2006-03-02 2007-09-13 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
WO2008069244A1 (ja) * 2006-12-05 2008-06-12 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
KR101510778B1 (ko) * 2007-07-12 2015-04-10 상가모 바이오사이언스 인코포레이티드 알파 1,6 당전이효소(ｆｕｔ8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물
ES2559007T3 (es) 2009-04-23 2016-02-10 Crucell Holland B.V. Alfa1 antitripsina humana recombinante

Also Published As

Publication number Publication date
US8357661B2 (en) 2013-01-22
CN102439037B (zh) 2015-01-07
CA2756591A1 (en) 2010-11-11
JP5711215B2 (ja) 2015-04-30
PL2421895T3 (pl) 2016-04-29
IL215537A (en) 2016-06-30
EA201171275A1 (ru) 2012-03-30
EP2421895A1 (en) 2012-02-29
AU2010244592A1 (en) 2011-10-27
IL215537A0 (en) 2011-12-29
KR101640962B1 (ko) 2016-07-19
AU2010244592B2 (en) 2016-05-19
WO2010127939A1 (en) 2010-11-11
CA2756591C (en) 2018-11-06
KR20120096871A (ko) 2012-08-31
EA025021B1 (ru) 2016-11-30
EP2421895B1 (en) 2015-11-11
ZA201107416B (en) 2017-11-29
US20120214747A1 (en) 2012-08-23
DK2421895T3 (en) 2016-01-25
JP2012524747A (ja) 2012-10-18
CN102439037A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
ES2559007T3 (es) Alfa1 antitripsina humana recombinante
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2512141T3 (es) Análogo peptídico de oxintomodulina
FR25C1003I1 (fr) Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
ES2528347T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal
ES2643764T3 (es) Preparación de productos sinterizados por reacción de circonia estabilizada con itria
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
PE20140617A1 (es) Alfa glucosidasa acida modificada con procesamiento acelerado
PT2437781E (pt) Composição estabilizada que compreende pelo menos um composto adrenérgico
AR072058A1 (es) Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
CR20130144A (es) Adhesivos de soja y compuestos hechos a partir de los adhesivos
CL2008001398A1 (es) Un circuito y metodo de control de iluminacion,que incluye un circuito reductor para reducir una fuente de iuminacion asociada con el circuito, y un circuito de deteccion de bombilla, para determinar el tipo de fuente de iluminacion asociada con el circuito reductor
AR058271A1 (es) Compuesto herbicida a base de fenoxaprop.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
BR112012019546A2 (pt) elemento de corte e metodo de orientacao
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
BRPI1012249A2 (pt) "composto de cromeno tendo uma estrutura, composição fotocrômica curável, artigo óptico,e, composto de naftol".
ES2536238T3 (es) Péptidos antimicrobianos
TR201908269T4 (tr) Ray dilatasyon düzeneği.
ES2526968T3 (es) Una composición agrícola, método para su producción y usos en el tratamiento de cultivos
GT200900245A (es) Nuevas formas solidas de un microbicida
BR112014014917A2 (pt) inibidores de fusão da membrana do hiv
ES2441880B1 (es) Composición basada en polipéptidos para el tratamiento de miasis